More Articles

Actavis plans entry to biosimilars market with Bioton agreement Pharma News | Posted 24/09/2010

In a press release on 7 September 2010, Icelandic generics’ manufacturer Actavis announced that it plans to enter into the field of biosimilars with an agreement with Polish biotechnology company,...

China set to give a big boost to biologics Policies & Legislation | Posted 24/09/2010

According to a report in a Chinese newspaper, China is planning to spend more than CNY 10 billion (US$1.5 billion) to support the development of new drugs between 2011 and 2016. Biotechnology was i...

Celgene and Natco in generic lenalidomide battle Generics/News | Posted 24/09/2010

Indian generics’ manufacturer Natco Pharma (Natco) has filed an abbreviated new drug application (ANDA) with the FDA seeking approval to sell a generic version of Celgene Corporation’s (Celgene’s)...

Price cuts, legislation and reforms Policies & Legislation | Posted 24/09/2010

In an effort to reduce budgets governments across the globe are lining up price cuts in prescription medicines, new legislation to control medicine prices and reforms in the healthcare systems. The...

Approval of biosimilar epoetins: how similar are they? Biosimilars/Research | Posted 24/09/2010

A consensus has emerged that approval of biosimilars requires both biological and clinical evidence. The ‘comparability exercise’ requires consideration of a wide range of aspects, including analyt...

Biosimilar epoetins: how similar are they? Biosimilars/Research | Posted 24/09/2010

As the patent expiry dates of the original erythropoietins drew near, much concern was expressed in 2004 about possible biosimilar competitors. Product quality, safety and efficacy of biopharmaceut...

New Zealand expects big savings with generic quetiapine Policies & Legislation | Posted 17/09/2010

The New Zealand pharmaceutical management agency, PHARMAC, expects to save NZ$24 million (US$17.1 million) over the next five years following price reductions for certain antipsychotic drugs. The a...

Ranbaxy to pay FDA to end impasse on manufacturing ban Pharma News | Posted 17/09/2010

Daiichi Sankyo hopes that its interventions may lead to a lift of the FDA’s import ban on 30 products from Ranbaxy, its Indian generic drugs arm.